Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors
Stoke Therapeutics (STOK) reported FDA alignment on Zorevunersen's approval pathway, with a composite endpoint for cognitive and behavioral assessments. The EMPEROR Phase III trial has 100% patient retention. The company plans to focus on 50 specialized centers for launch, treating half of U.S. Dravet syndrome patients. Stoke has $358.8M in cash, funding operations into 2028. STK-002 is in Phase I trials for autosomal dominant optic atrophy.


